AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Subscribe To Our Newsletter & Stay Updated